Hematopoietic cell transplantation for acute panmyelosis with myelofibrosis: a retrospective study in Japan
Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia (AML) in the World Health Organization classification [1]. APMF is characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly [2 –5]. A standard treatment has not been established for APMF. Treatment modalities for APMF have considerable heterogeneity, including chemotherapies such as danazol, lenalidomide, and zoledronate [2,3,6,7]. However, such treatments have limited efficacy and the vast majority of patients will die f rom progressive disease, such as bone marrow failure and development of overt AML.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Takaaki Konuma, Tadakazu Kondo, Takahito Kawata, Koji Iwato, Yuji Sato, Takehiko Mori, Kazuteru Ohashi, Hideyuki Nakazawa, Hiroyuki Sugahara, Hiroatsu Ago, Tetsuya Eto, Yutaka Imamura, Takahiro Fukuda, Yoshinobu Kanda, Yoshiko Atsuta, Shingo Yano, Adult A Tags: Brief Article Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | International Medicine & Public Health | Japan Health | Leukemia | Revlimid | Study | Transplants | WHO